Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities

Expert Opinion on Drug Safety
Julieta GonzálezMaría Sanjurjo Sáez

Abstract

Oral antineoplastic agents (OAA) have reached 30-50% of all antineoplastic treatments. Although they seem safer than parenteral therapy, many severe problems can occur if the dose is not adequately adjusted in special situations. Our objective is to create a comprehensive guide with dosage adjustment recommendations for OAA in cases of renal and hepatic impairment and hematologic toxicities. We analyzed all OAA approved by EMA in July 2017. We assessed data related to dose adjusted from the FDA's and EMA's summary of product characteristics. 53 OAA were analyzed. We identified 44 (83%) OAA requiring dosage adjustments in special situations: 20 (37.7%) in renal impairment, 37 (69.8%) in hepatic impairment, and 22 (41.5%) in patients with hematologic toxicity. The dose adjustment recommendations varied in 31 (58.5%) OAA between the FDA and EMA. Detailed recommendations for each OAA were collated into comprehensive tables. Most OAA have to be adjusted in special situations. Given the number of OAA available for different indications, this review can serve as an easy tool to help health professionals dose these complex treatments.

References

Aug 1, 1973·The British Journal of Surgery·R N PughR Williams
Jul 20, 2007·Cancer·Vincent Launay-VacherUNKNOWN Renal Insufficiency and Cancer Medications (IRMA) Study Group
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathleen E WalshJerry H Gurwitz
Oct 10, 2009·Clinical Genitourinary Cancer·Vincent Launay-VacherUNKNOWN Renal Insufficiency and Anticancer Medications (IRMA) Study Group
Nov 11, 2010·British Journal of Cancer·N JanusH Wildiers
Apr 28, 2012·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva·Leonor Periáñez-PárragaOlga Delgado-Sánchez
Apr 27, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rashmi R ShahDevron R Shah
Jan 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T O MattssonJ Herrstedt
May 15, 2015·Journal of Pharmacology & Pharmacotherapeutics·Jayanthi MathaiyanGitanjali Batmanabane
Sep 25, 2015·Targeted Oncology·Ying ChenYazdi K Pithavala
Jan 5, 2016·Journal of Geriatric Oncology·Grant R WilliamsHolly Holmes
Feb 13, 2016·European Journal of Cancer Care·V Escudero-VilaplanaM Sanjurjo-Saez
Feb 15, 2017·JAMA : the Journal of the American Medical Association·Richard S Klasco, Lewis H Glinert
Oct 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward S KimRichard L Schilsky

❮ Previous
Next ❯

Citations

Jul 10, 2019·Expert Opinion on Drug Safety·Vicente Escudero-VilaplanaMaría Sanjurjo-Saez
Mar 21, 2019·Clinical Journal of the American Society of Nephrology : CJASN·Morgan A CasalJan H Beumer
Dec 29, 2020·Cancer Treatment Reviews·Ben SprangersJolanta Malyszko

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Toxicology Letters
R F Borch, T J Montine
Critical Reviews in Oncology/hematology
Stuart M LichtmanSunitha Vemulapalli
© 2022 Meta ULC. All rights reserved